Liqing Kang
机构：Soochow University, Standard Bio (Norway), Shanghai Genon Biological Products (China), First Affiliated Hospital of Soochow University · ORCID：0000-0002-9840-9060
发表论文 122 篇 · 总被引 1830 次 · h-index 25
代表论文
- PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion (2024 · Journal for ImmunoTherapy of Cancer · 被引 57)
- CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial (2025 · Journal of Hematology & Oncology · 被引 19)
- BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma (2024 · Journal of Translational Medicine · 被引 10)
- Safe and potent anti‐CD19 CAR T‐cells with shRNA‐IL‐6 gene silencing element in patients with refractory or relapsed B‐cell acute lymphoblastic leukemia (2024 · HemaSphere · 被引 9)
- Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion (2024 · Cellular Oncology · 被引 9)
- CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia (2024 · Heliyon · 被引 5)